Article
Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer.
Scientific reports - 21 Apr 2023
Donker H C, van Es B, Tamminga M, Lunter G A, van Kempen L C L T, Schuuring E, Hiltermann T J N, Groen H J M
Abstract excerpt
In advanced non-small cell lung cancer (NSCLC), response to immunotherapy is difficult to predict from pre-treatment information. Given the toxicity of immunotherapy and its financial burden on the healthcare system, we set out to identify patients for whom treatment is effective. To this end, we used mutational signatures from DNA mutations in pre-treatment tissue. Single base substitutions, doublet base...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.